Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis - Abstract
Urinary tract infections (UTIs) were reported frequently with dalfampridine extended-release (dalfampridine-ER) 10 mg relative to placebo in previous multiple sclerosis (MS) studies.